Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
LNTH 
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: LNTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $80.93
1 Year Target Price $80.93
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.08% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.14B USD | Price to earnings Ratio 25.26 | 1Y Target Price 80.93 |
Price to earnings Ratio 25.26 | 1Y Target Price 80.93 | ||
Volume (30-day avg) 13 | Beta -0.1 | 52 Weeks Range 47.25 - 111.29 | Updated Date 12/10/2025 |
52 Weeks Range 47.25 - 111.29 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.99% | Operating Margin (TTM) 11.36% |
Management Effectiveness
Return on Assets (TTM) 9.93% | Return on Equity (TTM) 14.59% |
Valuation
Trailing PE 25.26 | Forward PE 10.65 | Enterprise Value 4274492105 | Price to Sales(TTM) 2.71 |
Enterprise Value 4274492105 | Price to Sales(TTM) 2.71 | ||
Enterprise Value to Revenue 2.8 | Enterprise Value to EBITDA 13.08 | Shares Outstanding 66311779 | Shares Floating 61464388 |
Shares Outstanding 66311779 | Shares Floating 61464388 | ||
Percent Insiders 2.32 | Percent Institutions 110.95 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings Inc. (LNTH) was founded in 2001 as a spin-off from Eastman Kodak's imaging business. It has since evolved into a dedicated diagnostics and therapeutics company, focusing on areas like nuclear medicine. Key milestones include its IPO in 2015 and subsequent strategic acquisitions and product launches that have reshaped its portfolio and market presence.
Core Business Areas
- Radiopharmaceuticals: Development, manufacturing, and commercialization of diagnostic and therapeutic radiopharmaceuticals used in medical imaging and cancer treatment.
- Contract Manufacturing: Provides contract manufacturing services for radiopharmaceuticals to other pharmaceutical companies.
- Imaging Agents: Offers a range of contrast agents and ultrasound microbubbles used in medical imaging procedures to enhance visualization of anatomical structures and physiological processes.
Leadership and Structure
Lantheus Holdings Inc. is led by a management team with extensive experience in the pharmaceutical and medical device industries. The company operates with a divisional structure, aligned with its core business areas to drive innovation and market penetration in each segment.
Top Products and Market Share
Key Offerings
- DEFINITYu00ae: A non-imaging ultrasound enhancement agent that improves the visualization of cardiac structures during echocardiography. Competitors include GE Healthcare's Definity and other ultrasound contrast agents. Market share is significant within its niche.
- PYLARIFYu00ae: A prostate-specific membrane antigen (PSMA) PET imaging agent for detecting PSMA-positive lesions in men with prostate cancer. Competitors include other PSMA-targeting agents from companies like Novartis (Pluvicto) and others in development. Represents a growing segment for Lantheus.
- X-RAYLINKu2122: A contrast agent used in diagnostic imaging. Competitors include major pharmaceutical companies offering iodinated contrast media. Market share is established within its product category.
Market Dynamics
Industry Overview
The medical imaging and radiopharmaceuticals market is characterized by continuous innovation, increasing demand for advanced diagnostic tools, and a growing focus on personalized medicine. Key trends include the rise of PET imaging, the development of targeted therapies, and the increasing complexity of drug development and manufacturing.
Positioning
Lantheus Holdings Inc. is strategically positioned as a leader in nuclear medicine and a significant player in the ultrasound contrast agent market. Its strength lies in its specialized portfolio, particularly in radiopharmaceuticals, and its established manufacturing capabilities.
Total Addressable Market (TAM)
The total addressable market for medical imaging agents, radiopharmaceuticals, and related services is substantial and growing, estimated to be in the tens of billions of dollars globally. Lantheus Holdings Inc. targets specific segments within this TAM, with its PSMA PET imaging agent and ultrasound enhancers addressing significant unmet needs and high-growth areas. The company is well-positioned to capture a growing share of these specialized markets.
Upturn SWOT Analysis
Strengths
- Strong portfolio of specialized radiopharmaceuticals and imaging agents.
- Established manufacturing capabilities for radiopharmaceuticals.
- Growing market presence with products like PYLARIFYu00ae.
- Experienced management team.
- Partnerships and collaborations for product development and distribution.
Weaknesses
- Reliance on a few key products for a significant portion of revenue.
- Potential for regulatory hurdles and lengthy approval processes for new products.
- Competition from larger, more diversified pharmaceutical companies.
- Geographic concentration of sales in North America.
Opportunities
- Expansion of radiopharmaceutical pipeline through R&D and acquisitions.
- Geographic expansion into new international markets.
- Increasing demand for advanced diagnostic imaging in oncology and cardiology.
- Leveraging contract manufacturing capabilities.
- Development of companion diagnostics and therapeutic combinations.
Threats
- Intensifying competition from both established players and emerging biotech companies.
- Pricing pressures and reimbursement challenges from payors.
- Changes in regulatory landscape and approval requirements.
- Supply chain disruptions for raw materials.
- Technological advancements by competitors that could render current products obsolete.
Competitors and Market Share
Key Competitors
- GE HealthCare (GEHC)
- Cardinal Health (CAH)
- Bayer AG (BAYRY - ADR)
- Johnson & Johnson (JNJ)
- Novartis AG (NVS)
Competitive Landscape
Lantheus holds a strong position in niche areas like PSMA PET imaging, where it is a first-mover with PYLARIFYu00ae. Its competitive advantages lie in its focused portfolio, specialized expertise in radiopharmaceuticals, and a dedicated sales and distribution network. However, it faces competition from larger, more diversified companies with broader product portfolios and greater R&D budgets. Key differentiators for Lantheus include its speed to market with innovative radiopharmaceuticals and its patient-centric approach.
Major Acquisitions
Progenics Pharmaceuticals, Inc.
- Year: 2020
- Acquisition Price (USD millions): 504
- Strategic Rationale: Acquired to significantly expand Lantheus's radiopharmaceutical portfolio, including its flagship prostate cancer imaging agent, PSMA diagnostic, and therapeutic pipeline, establishing a strong foothold in oncology diagnostics and therapeutics.
Cymbet Corporation
- Year: 2018
- Acquisition Price (USD millions): 60
- Strategic Rationale: Acquisition of a battery technology company to explore integration into medical devices, aiming to enhance product performance and create new opportunities in wearable or implantable devices.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has experienced strong historical growth, particularly in the last few years, driven by the successful commercialization of its radiopharmaceutical offerings. Acquisitions have also played a role in expanding its product portfolio and market reach.
Future Projections: Analyst estimates generally project continued robust revenue growth for Lantheus Holdings Inc., supported by the expansion of its radiopharmaceutical franchise, particularly PYLARIFYu00ae, and potential pipeline advancements. Earnings growth is also expected to outpace revenue growth as the company achieves economies of scale.
Recent Initiatives: Recent initiatives include ongoing clinical trials for new radiopharmaceuticals, strategic partnerships to expand market access, and continuous efforts to enhance manufacturing capacity and supply chain reliability.
Summary
Lantheus Holdings Inc. is a robust player in the radiopharmaceuticals and medical imaging sector, with a strong focus on oncology and cardiology. Its strategic acquisitions and pipeline development, particularly PYLARIFYu00ae, have driven significant growth and market recognition. The company's specialized expertise and manufacturing capabilities are key strengths. However, it must navigate intense competition, regulatory complexities, and potential pricing pressures to sustain its upward trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Research Reports
- Company Investor Relations Materials
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data and financial metrics are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.